{
  "1B1.F": {
    "city": "Warsaw",
    "country": "Poland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "OncoArendi Therapeutics S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ONCOARENDI THERAP  ZY-,01",
    "state": null,
    "summary": "OncoArendi Therapeutics S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was founded in 2012 and is headquartered in Warsaw, Poland.",
    "website": "http://www.oncoarendi.com",
    "zipcode": "02-089"
  },
  "272.F": {
    "city": "KonstantynÃ³w LÃ³dzki",
    "country": "Poland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Mabion S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MABION SA  ZY -,10",
    "state": null,
    "summary": "Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of malignant, autoimmune, and metabolic diseases. Its products include MabionCD20, MabionHER2, MabionEGFR, and MabionVEGF that are oncology drugs; and MabionVEGF_Fab to treat several diseases resulting in vision impairment. The company was founded in 2007 and is based in KonstantynÃ³w LÃ³dzki, Poland.",
    "website": "http://www.mabion.eu",
    "zipcode": "95-050"
  },
  "6NQ.F": {
    "city": "Lublin",
    "country": "Poland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOMED-LUBLIN WYT.SUR.",
    "state": null,
    "summary": "BIOMED-LUBLIN WytwÃ³rnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 and Gamma anty-HBs 1000 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; LÃ¶wenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; LÃ¶wenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland.",
    "website": "http://biomedlublin.com",
    "zipcode": "20-029"
  },
  "8RP.F": {
    "city": "Lomianki",
    "country": "Poland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Celon Pharma S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELON PHARMA S.A. ZY-,10",
    "state": null,
    "summary": "Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.",
    "website": "http://www.celonpharma.com",
    "zipcode": "05-092"
  },
  "9Y4.F": {
    "city": "KrakÃ³w",
    "country": "Poland",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Ryvu Therapeutics S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RYVU THERAPEUTICS  ZY-,40",
    "state": null,
    "summary": "Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment of oncology. Its lead candidate, SEL120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group has completed Phase 1 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in KrakÃ³w, Poland.",
    "website": "http://www.ryvu.com",
    "zipcode": "30-394"
  },
  "PQB.SG": {
    "city": "Wroclaw",
    "country": "Poland",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Pure Biologics Spólka Akcyjna",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Pure Biologics S.A. Inhaber-Akt",
    "state": null,
    "summary": "Pure Biologics SpÃ³lka Akcyjna, a biopharmaceutical company, engages in the research and development of new therapies and diagnostic methods in the field of immuno-oncology and rare diseases. It is also involved in the production, purification, analysis, and characterization of recombinant proteins and antibodies, protein engineering and formulation, genome sequencing, proteomic analysis, and bioinformatics; development and validation of assays; development of measurement methods and the derivation of stable cell lines; and provision of contract research service related to lead identification from antibody and aptamer libraries. In addition, the company offers medical devices; cancer diagnostics products; PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use; and Pure Select2, a platform for in vitro selection of recombinant human antibody fragments that recognize a chosen molecular target, including whole cells. Further, it undertakes partnership projects in cooperation with various institutions, which include Molecular Analytical Robotics Assays (MARA), which focuses on the development of modern nanotechnologies in the diagnosis and treatment of bacterial infections; MAGBBRIS project that investigate growth factors secreted by endothelial progenitor cells; and APIFAG project, a bacteriophage preparation intended for the prevention and treatment of American Foulbrood and European Foulbrood in honeybees, as well as various other projects funded by the European Union. The company was founded in 2010 and is based in Wroclaw, Poland.",
    "website": "http://www.purebiologics.com",
    "zipcode": "54-427"
  }
}
